Company intelligence / Profile preview

Menlo Therapeutics

Redwood City, California, United States

Ownership: Private
Development stage: Other

Overview

The company's lead program, serlopitant (VPD-737), demonstrated positive results in Phase 2 clinical trials for chronic pruritus and prurigo nodularis, meeting primary and secondary endpoints in over 380 patients. Preparation for Phase 3 trials for prurigo nodularis and further development in related indications were underway as of 2018.[2][4][6][10]

Therapeutic areas: DermatologyPulmonology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

serlopitant

Partnerships

Merck (licensor of serlopitant)Velocity Pharmaceutical Holdings (founder/investor)Remeditex Ventures (investor)Presidio PartnersVivo CapitalvenBio Global Strategic Fund IIF-PrimeNovo Holdings A/SRock Springs CapitalAisling CapitalBay City Capital

Beyond the preview

Go deeper on Menlo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Menlo Therapeutics.

Explore the full profile